CLINICAL TRIAL SUMMARY

MDACC Study No:2013-0527 (clinicaltrials.gov NCT No: NCT01943851)
Title:A phase I/II open-label, dose escalation study to investigate the
safety, pharmacokinetics, pharmacodynamics and clinical
activity of GSK525762 in subjects with relapsed, refractory
hematologic malignancies
Principal Investigator:Gautam Borthakur
Treatment Agent:GSK525762
Study Status:Open
Study Description:The goal of Part 1 of this clinical research study is to find the highest
tolerable dose of GSK525762 that can be given to patients with refractory or
relapsed leukemia. The safety of this drug will also be studied.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:GSK525762
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:GlaxoSmithKline
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gautam Borthakur
Dept:Leukemia
For Clinical Trial Enrollment:713-563-1586
For General Questions about Clinical Trials:1-877-MDA-6789


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults